Technology Reports of Kansai University (ISSN: 04532198) is a monthly peer-reviewed and open-access international Journal. It was first built in 1959 and officially in 1975 till now by kansai university, japan. The journal covers all sort of engineering topic, mathematics and physics. Technology Reports of Kansai University (TRKU) was closed access journal until 2017. After that TRKU became open access journal. TRKU is a scopus indexed journal and directly run by faculty of engineering, kansai university.
Technology Reports of Kansai University (ISSN: 04532198) is a peer-reviewed journal. The journal covers all sort of engineering topic as well as mathematics and physics. the journal's scopes are
in the following fields but not limited to:
Azerbaijan Medical Journal
Gongcheng Kexue Yu Jishu/Advanced Engineering Science
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
Interventional Pulmonology
Zhenkong Kexue yu Jishu Xuebao/Journal of Vacuum Science and Technology
Wuhan Ligong Daxue Xuebao (Jiaotong Kexue Yu Gongcheng Ban)/Journal of Wuhan University of Technology (Transportation Science and Engineering)
Zhonghua yi shi za zhi (Beijing, China : 1980)
An investigation was conducted to determine the effect of plasma activated Aloe vera slice on for wound contraction in a small animal model by mimicking a clinical setting. An atmospheric plasma jet using medical grade argon gas as a carrier gas. Twelve experimental mouse Balb c, male, age 7-8 weeks, were classified into 4 groups, namely, Control (C), Aloe vera slice alone (A), Plasma activated Aloe vera slice with distance 10 mm (PAV-10) and Plasma activated Aloe vera slice with distance 20 mm (PAV-20). Aloe vera slices with thickness about 2 mm was prepared. They were treated by atmospheric plasma jet with distance 10 mm and 20 mm during 2 minutes before their application. Macroscopic use the visual evaluation of wounds was evaluated for 14 days. Wound contraction was calculated using a mathematic formula based on wound area measurement supported by computer software Scion. This investigation showed that wound contraction percentage in groups containing Aloe vera were higher than that in control group. This investigation was also showed that during proliferative phase, wound contraction percentage in PAV-20 was higher than that in PAV-10. On days 4-7 whilst that in the first group was slightly lower than that in the A, that in the second group was higher than that in the A. PAV-20 may have ability to accelerate wound healing, while PAV-10 may have ability to impede it. It was concluded that different characteristic of plasma activated Aloe vera slice may cause different effect on wound
National HIV patient participation in receiving antiretroviral (ARV) therapy is 33%. HIV patients undergoing ARV therapy complain of the emergence of therapeutic toxicity. The purpose of this study was to determine the immunodeficiency stage (CD4 cell count) and degree of toxicity (hematological and clinical chemistry values). This type of research is descriptive research. Data collection was carried out using the cross-sectional method. Data collection involved 32 HIV patients who received ARV therapy services in KRT Setjonegoro Regional Hospital. The study subjects were determined non-randomly with the criteria: having undergone controlled therapy >6 months and aged ≥15 years. The exclusion criteria for this study were patients referred out of care during the study. This research activity has received approval (ethical clearance) Research Ethics Commission of the Faculty of Medicine, Gajah Mada University. The results of this study for the characteristics of patients as many as 19 people (59.40%) are male and 13 people (40.60%) are female. Age of HIV patients 18-44 years as many as 29 people (90.60%) and 45-59 years as many as 3 people (9.40%). Education of elementary school patients as many as 13 people (40.60%), secondary schools 14 people (43.80%) and colleges 5 people (15.60%). Clinical stage of the patient, stadium 1 were 14 people (43.80%), stage 2 were 4 people (12.50%), stage 3 were 2 people (37.50%) and stage 4 were 2 people (6.30%). The efficacy of patients with CD4 parameters showed 17 patients (53.00%) patients did not experience immunodeficiency and mild toxicity experienced by 2 patients (6.30%) HIV who received antiretroviral therapy
